$ALZN
Alzamend Neuro, Inc.

2023 Q3 Form 10-Q Financial Statement

#000121465923012326 Filed on September 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.160M $1.660M
YoY Change -30.1% 19.41%
% of Gross Profit
Research & Development $2.366M $1.376M
YoY Change 71.96% 50.15%
% of Gross Profit
Depreciation & Amortization $12.69K $7.097K
YoY Change 78.74%
% of Gross Profit
Operating Expenses $3.526M $1.376M
YoY Change 156.25% -40.34%
Operating Profit -$3.526M -$3.036M
YoY Change 16.15% 31.62%
Interest Expense $1.835K $1.532K
YoY Change 19.78% -111.24%
% of Operating Profit
Other Income/Expense, Net -$1.835K -$1.532K
YoY Change 19.78% -88.76%
Pretax Income -$3.530M -$3.037M
YoY Change 16.23% 30.92%
Income Tax
% Of Pretax Income
Net Earnings -$3.528M -$3.037M
YoY Change 16.16% 30.92%
Net Earnings / Revenue
Basic Earnings Per Share -$0.04 -$0.03
Diluted Earnings Per Share -$0.04 -$31.16K
COMMON SHARES
Basic Shares Outstanding 96.94M shares 95.48M shares
Diluted Shares Outstanding 98.44M shares 97.48M shares

Balance Sheet

Concept 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.700M $11.53M
YoY Change -85.25% -26.19%
Cash & Equivalents $1.695M $11.53M
Short-Term Investments
Other Short-Term Assets $720.0K $578.1K
YoY Change 24.54% -51.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.414M $12.11M
YoY Change -80.08% -27.96%
LONG-TERM ASSETS
Property, Plant & Equipment $214.4K $95.81K
YoY Change 123.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $214.4K $95.81K
YoY Change 123.77%
TOTAL ASSETS
Total Short-Term Assets $2.414M $12.11M
Total Long-Term Assets $214.4K $95.81K
Total Assets $2.628M $12.21M
YoY Change -78.48% -27.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.741M $1.029M
YoY Change 166.44% -4.09%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.740M $1.029M
YoY Change 166.36% -30.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.740M $1.029M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $2.741M $1.029M
YoY Change 166.44% -30.18%
SHAREHOLDERS EQUITY
Retained Earnings -$47.60M -$32.23M
YoY Change 47.68% 68.29%
Common Stock $9.694K $9.548K
YoY Change 1.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$112.9K $11.18M
YoY Change
Total Liabilities & Shareholders Equity $2.628M $12.21M
YoY Change -78.48% -27.39%

Cashflow Statement

Concept 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$3.528M -$3.037M
YoY Change 16.16% 30.92%
Depreciation, Depletion And Amortization $12.69K $7.097K
YoY Change 78.74%
Cash From Operating Activities -$3.298M -$2.537M
YoY Change 30.02% 107.47%
INVESTING ACTIVITIES
Capital Expenditures $150.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$147.2K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$3.298M -$2.537M
Cash From Investing Activities -$147.2K
Cash From Financing Activities
Net Change In Cash -$3.445M -$2.537M
YoY Change 35.82%
FREE CASH FLOW
Cash From Operating Activities -$3.298M -$2.537M
Capital Expenditures $150.0K
Free Cash Flow -$3.448M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001677077
CY2023Q3 dei Amendment Flag
AmendmentFlag
false
CY2023Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
CY2023Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q3 alzm Increase Decrease In Prepaid Expenses Related Party
IncreaseDecreaseInPrepaidExpensesRelatedParty
usd
CY2022Q3 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
usd
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q3 alzm Shares Available For Grant Options Granted
SharesAvailableForGrantOptionsGranted
shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q3 alzm Shares Available For Grant Options Exercised
SharesAvailableForGrantOptionsExercised
shares
CY2023Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q3 alzm Shares Available For Grant Options Expired
SharesAvailableForGrantOptionsExpired
shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q3 dei Document Type
DocumentType
10-Q
CY2023Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q3 dei Document Period End Date
DocumentPeriodEndDate
2023-07-31
CY2023Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q3 dei Entity File Number
EntityFileNumber
001-40483
CY2023Q3 dei Entity Registrant Name
EntityRegistrantName
ALZAMEND NEURO, INC.
CY2023Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-1822909
CY2023Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
3480 Peachtree Road NE
CY2023Q3 dei Entity Address Address Line2
EntityAddressAddressLine2
Second Floor
CY2023Q3 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 103
CY2023Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Atlanta
CY2023Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2023Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30326
CY2023Q3 dei City Area Code
CityAreaCode
(844)
CY2023Q3 dei Local Phone Number
LocalPhoneNumber
722-6303
CY2023Q3 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q3 dei Trading Symbol
TradingSymbol
ALZN
CY2023Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q3 dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
96940124 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1695416 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5140859 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
718188 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
447589 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
247334 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
2413604 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
5835782 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
214401 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79843 usd
CY2023Q3 us-gaap Assets
Assets
2628005 usd
CY2023Q2 us-gaap Assets
Assets
5915625 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2740888 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2870122 usd
CY2023Q3 us-gaap Liabilities
Liabilities
2740888 usd
CY2023Q2 us-gaap Liabilities
Liabilities
2870122 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
96940124 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
96940124 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
96940124 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
96940124 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
9694 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
9694 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
62361146 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
61991766 usd
CY2023Q3 alzm Note Receivable For Common Stock Related Party
NoteReceivableForCommonStockRelatedParty
-14883295 usd
CY2023Q2 alzm Note Receivable For Common Stock Related Party
NoteReceivableForCommonStockRelatedParty
-14883295 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47600428 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44072662 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-112883 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3045503 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2628005 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5915625 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2366137 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1375953 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1159794 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1659589 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3525931 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
3035542 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3525931 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3035542 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
1835 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
1532 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1835 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1532 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3527766 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3037074 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98440124 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98440124 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97481790 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97481790 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3045503 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
369380 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3527766 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-112883 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
13351511 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
867338 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3037074 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
11181775 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3527766 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3037074 usd
CY2023Q3 us-gaap Depreciation
Depreciation
12685 usd
CY2022Q3 us-gaap Depreciation
Depreciation
7097 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
369380 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
867338 usd
CY2023Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
270599 usd
CY2022Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
237819 usd
CY2023Q3 alzm Increase Decrease In Prepaid Expenses Related Party
IncreaseDecreaseInPrepaidExpensesRelatedParty
-247334 usd
CY2023Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-129234 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-136232 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3298200 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2536690 usd
CY2023Q3 us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
147243 usd
CY2023Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-147243 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3445443 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2536690 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5140859 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14063811 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1695416 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11527121 usd
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28358117 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28824788 shares
CY2023Q3 alzm Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
P5Y11M4D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
678900 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
13808329 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Cash
Cash
1700000 usd
CY2023Q3 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
47600000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
113000 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
3500000 usd
CY2023Q3 alzm Cash Used In Operating Activities
CashUsedInOperatingActivities
3300000 usd
CY2023Q3 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_z22HqrhNwCL3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in"><b><i>Accounting Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.8pt">The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company’s significant accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
9191671 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14808329 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.22
CY2023Q3 alzm Long Term Debt Average Amount Of Outstanding
LongTermDebtAverageAmountOfOutstanding
14883295 usd
CY2023Q3 alzm Long Term Debt Average Amount Of Outstanding
LongTermDebtAverageAmountOfOutstanding
14883295 usd
CY2023Q3 alzm Prepaid Clinical Trial Fees
PrepaidClinicalTrialFees
394821 usd
CY2023Q2 alzm Prepaid Clinical Trial Fees
PrepaidClinicalTrialFees
352635 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
311533 usd
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
92154 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
11834 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2800 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
718188 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
447589 usd
CY2022Q2 alzm Purchase Director And Officer Insurance
PurchaseDirectorAndOfficerInsurance
337000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
9191671 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14808329 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.22
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M4D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
819900 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.22
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y8M4D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
678900 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
13401031 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.20
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M9D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
678900 usd
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10149788 shares
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P1Y7M6D
CY2023Q3 alzm Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
2.90
CY2023Q3 alzm Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
10149788 shares
CY2023Q3 alzm Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
2.90
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001

Files In Submission

Name View Source Status
0001214659-23-012326-index-headers.html Edgar Link pending
0001214659-23-012326-index.html Edgar Link pending
0001214659-23-012326.txt Edgar Link pending
0001214659-23-012326-xbrl.zip Edgar Link pending
alzm-20230731.xsd Edgar Link pending
ex31_1.htm Edgar Link pending
ex31_2.htm Edgar Link pending
ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
alzm-20230731_cal.xml Edgar Link unprocessable
alzm-20230731_lab.xml Edgar Link unprocessable
alzm-20230731_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
alzm-20230731_def.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
r9523010q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
r9523010q_htm.xml Edgar Link completed